We are monitoring the impact of COVID-19 & Recession alarm on Europe Therapeutic Vaccines Market Get in touch with us for detailed analysis Know More
Share on

Europe Therapeutic Vaccines Market Research Report – Segmented By Disease Type (Autoimmune Disease, Cancer, Neurological Disease, Infectious Disease) and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 57
Pages: 141

Europe Therapeutic Vaccines Market Size (2022 to 2027)

The size of the European Therapeutic Vaccines Market was estimated at 926.60 million USD in 2022. It is further expected to grow and be worth 3637.96 million USD by 2027, growing at a CAGR of 31.46% between 2022 and 2027.

Some of the factors propelling the European therapeutic vaccines market ahead include increased government funding for vaccine development, increased investments by leading market players, rising illness prevalence, technical advancements, and NGOs' activities.

Therapeutic vaccinations have grown in popularity as the prevalence of illnesses like cancer and HIV has increased. Technological advancements in HIV detection and expanded clinical trials for HIV and cancer vaccinations are two crucial factors accelerating the European therapeutic vaccines market. Furthermore, greater public awareness of critical illnesses and increased R&D spending in therapeutic vaccines boost the market for therapeutic vaccines in this region.

The massive growth has considerably influenced the European market for therapeutic vaccines in the prevalence of chronic illnesses such as cancer, HIV, and cardiovascular disorders. The world's attention has switched to therapeutic vaccinations as the need for effective therapy has risen alarmingly. Several pharmaceutical companies have developed novel vaccines for breast cancer, lung cancer, and Alzheimer's disease. Even though these developments are still in the works and have yet to be marketed, they indicate a new market potential for therapeutic vaccines throughout the world. Furthermore, malignancies caused by the human papillomavirus are anticipated to create a growing potential for the therapeutic vaccines market in Europe. 

Massive capital expenditures, strict regulatory restrictions, and expensive treatment costs are only a few factors that diminish the market's growth. Higher vaccination prices and a lack of therapeutic medication availability are limiting the European therapeutic vaccines market. Furthermore, tight regulatory criteria for therapeutic vaccine approval impeded the global therapeutic vaccines market. Ineffective research and development policies, as well as reimbursement regulations, are limiting the market. On the other hand, vaccination can cure a wide spectrum of chronic conditions, and these limitations will fade with time.

Clinical studies must be completed before a vaccine may be offered commercially. The majority of immunizations are rejected at every stage of the clinical study. By the time the finished product is licensed for commercial use, a significant amount of money has been spent on vaccine development R&D. These are some of the key challenges the market is currently facing.

This research report on the European therapeutic vaccines market has been segmented and sub-segmented into the following categories:

By Disease Type: 

  • Autoimmune Disease
  • Cancer
  • Neurological Disease
  • Infectious Disease

By Country: 

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Geographically, Europe is in a close race with North America in terms of market share in the global therapeutic vaccines market. A rise in autoimmune disease-related fatalities among women and children is to satisfy commercial demand. In addition, the market demand in this area is increasing as healthcare centers with novel procedures for chronic and deadly diseases grow.

The rise in the incidence of numerous chronic illnesses, including cancer, HIV, and cardiovascular diseases, has substantially influenced Europe's therapeutic vaccination industry. Because of the worrisome rise in demand for effective therapy, several pharmaceutical firms have begun developing innovative vaccinations for illnesses such as breast cancer, lung cancer, and Alzheimer's disease. The world's attention has shifted to therapeutic vaccines.  Therefore, despite the fact that these technologies are still in development and have yet to be commercialized, they point to a bright future for Europe's therapeutic vaccine market. 

KEY MARKET PLAYERS:

Companies playing a pivotal role in the European therapeutic vaccines market covered in this report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                               

                2.2 Analysis Design                                                         

                2.3 Research Phases                                                      

                                2.3.1 Secondary Research                                           

                                2.3.2 Primary Research                                 

                                2.3.3 Econometric Modelling                                      

                                2.3.4 Expert Validation                                  

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

  1. Market Segmentation

                5.1 By Disease Type                                                       

                                5.1.1 Autoimmune Disease Vaccines                                      

                                5.1.2 Cancer Vaccines                                    

                                                5.1.2.1 Multikine                             

                                                5.1.2.2 PR1 Peptide                        

                                                5.1.2.3 TroVax                  

                                                5.1.2.4 CYT004-MelQbG10                           

                                5.1.3 Neurological Disease Vaccines                                        

                                                5.1.3.1 ACC- 001                               

                                                5.1.3.2 CAD 106                

                                                5.1.3.3 Parkinson's Disease Vaccine                        

                                                5.1.3.4 Alzheimer's Disease                        

                                5.1.4 Infectious Disease Vaccines                                             

                                                5.1.4.1 Hepatitis C                           

                                                5.1.4.2 HIV/AIDS                              

                                                5.1.4.3 Other Infectious Disease                               

  1. Geographical Analysis

                6.1 Introduction                                                               

                6.2 U.K                                                 

                6.3 Spain                                                             

                6.4 Germany                                                     

                6.5 Italy                                                               

                6.6 France                                                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

  1. Market Leaders' Analysis

                8.1 GlaxoSMithKline plc.                                                              

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                             

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Merck and Company                                                              

                8.3 Bavarian Nordic                                                        

                8.4 CSL Limited                                                 

                8.5 Emergent Biosolutions Inc.                                                  

                8.6 Novartis AG                                                

                8.7 Johnson and Johnson                                                            

                8.8 MedImmune LLC                                                     

                8.9 Pfizer Inc.                                                    

                8.10 Sanofi Pasteur                                                        

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

     Appendix                                                                           

  1. List of Tables
  2. List of Figures
  1. Europe Therapeutic Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  2. Europe Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Billion)
  3. Europe Autoimmune Disease Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  5. Europe Neurological Disease Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  6. Europe Infectious Disease Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  7. Europe Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  8. Europe Multikine Market, By Region, From 2022 - 2027 (USD Billion)
  9. Europe PR1 Peptide Market, By Region, From 2022 - 2027 (USD Billion)
  10. Europe TroVax Market, By Region, From 2022 - 2027 (USD Billion)
  11. Europe CYT004-MelQbG10 Market, By Region, From 2022 - 2027 (USD Billion)
  12. Europe Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  13. Europe ACC- 001 Market, By Region, From 2022 - 2027 (USD Billion)
  14. Europe CAD 106 Market, By Region, From 2022 - 2027 (USD Billion)
  15. Europe Parkinson's Vaccine Market, By Region, From 2022 - 2027 (USD Billion)
  16. Europe Alzheimer's Vaccine Market, By Region, From 2022 - 2027 (USD Billion)
  17. Europe Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  18. Europe Hepatitis C Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  19. Europe HIV/AIDS Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  20. Europe Other Infectious Disease Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  21. U.K. Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Billion)
  22. Germany Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Billion)
  23. France Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Billion)
  24. Italy Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Billion)
  25. Spain Therapeutic Vaccines Market, By Disease Type, From 2022 - 2027 (USD Billion)
  26. U.K. Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  27. Germany Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  28. France Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  29. Italy Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  30. Spain Cancer Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  31. U.K. Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  32. Germany Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  33. France Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  34. Italy Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  35. Spain Neurological Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  36. U.K. Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  37. Germany Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  38. France Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  39. Italy Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  40. Spain Infectious Disease Vaccines Market, By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample